Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Trends in psychiatric emergency visits: insights from France's largest psychiatric emergency department.
Int J Emerg Med
January 2025
Centre Psychiatrique d'Orientation Et d'Accueil (CPOA), GHU Paris Psychiatrie Et Neurosciences, Site Sainte-Anne, 1 Rue Cabanis, Paris, 75014, France.
Introduction: Psychiatric emergency departments (EDs) in France have been under pressure from several factors, exacerbated by the COVID-19 pandemic. The pandemic led to an increase in psychiatric disorders, particularly anxiety and depression, with younger people and women being most affected. The aim of this study was to provide a comprehensive description of the trends in the number of visits to the largest psychiatric emergency department in France, with a particular focus on the period preceding and following the advent of COVID-19 pandemic.
View Article and Find Full Text PDF"Real-Life" Data of Zanubrutinib in Patients with Waldenström Macroglobulinemia: A Multicenter Retrospective Study.
Acta Haematol
December 2024
School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Introduction: Waldenström macroglobulinemia (WM) is a rare indolent lymphoma. Zanubrutinib (ZAN), a second-generation BTK inhibitor, has been approved for the treatment of WM in any line of therapy in 2021. Between November 2020 and January 2022, an expanded access program of ZAN opened in Israel for the treatment of patients with relapsed/refractory (R/R)-WM or those ineligible for chemotherapy or ibrutinib in first line.
View Article and Find Full Text PDFPatient Travel Patterns and Concordance With Geographic Market Boundaries.
Ann Intern Med
December 2024
Agency for Healthcare Research and Quality, Rockville, Maryland.
Asciminib in Advanced-Line Treatment of Chronic Myeloid Leukemia.
Eur J Haematol
February 2025
School of Medicine, Faculty of Medicine and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
Objectives: Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the ABL1 myristoyl pocket to potentially reduce toxicity and enhance efficacy. It is approved for Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia (CML-CP) in patients with resistance or intolerance to two or more tyrosine kinase inhibitors (TKIs) or those with the T315I mutation.
Methods: This retrospective analysis evaluated patients with CML treated with asciminib under a managed-access program across eight Israeli centers from July 2019 to August 2022.
[When psychiatrists and neurologists work together: From acute and transient psychotic disorder to autoimmune encephalitis].
Encephale
October 2024
Centre Psychiatrique d'Orientation et d'Accueil (CPOA), GHU Paris psychiatrie & neurosciences, Paris, France.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!